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Abstract 
The aim of this study was prepare and evaluate floating granules of sodium 
diclofenac with lipid excipient for prolonged gastric residence and reduced 
dose regimen. Floating granules prepared by extruder-spheronization 
technique. Compritol and gelucire as lipid excipient, HPMC as retardant and 
tween 80 as emulsifier were used. The effect of drug/lipid, drug/HPMC, drug 
amount, percentage of tween and type of lipid on floating ability, morphology 
and dissolution parameters were evaluated by factorial design. Results 
showed floating ability of granules was influenced by proportion of 
drug/lipid, drug/HPMC and percentage of tween. Floating property of 
Compritol was more than gelucire and provided good floating particles. 
Compritol granules provided suitable sustained release pattern in the manner 
that increase in D/L reduced D8 and MDT and increase in %T increased 
MDT. Higuchi model was the best fitted for dissolution data of granules 
prepared by Compritol and gelucire. In conclusion, Compritol provided more 
suitable floating ability and sustained release property. 
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Introduction  
The oral drug delivery has more attention among the 
different routs of drug administration. Regretfully, the 
variability of gastrointestinal physiology same as 
gastric emptying time, pH and agitation to cause an 
unpredictable bioavailability and lack of drug 
effectiveness. Prolongation of gastric time with 
sustained release systems leads to reduction the 
number of dosage regimen and improvement of drug 
bioavailability [1]. Different methods have been 
applied to keeping the dosage form in stomach 
including bioadhesive systems, swelling and floating 
systems [2]. Permanent retention is propounded for 
swelling system and irritation of the mucous layer for 
bioadhesive systems [3].  
 
The use of high density solid dosage forms which 
remain in the down part of stomach have been 
applied. But bioavailability of them are unpredictable 
[4]. Floating systems to be more useful and protection 
against early and random gastric evacuation compare 
to other dosage forms that are used for this purpose. 
The effect of single-unit floating systems on gastric 
emptying time is non-reproducible and unpredictable. 
On the other hand, multiple-unit floating systems 
same as pellets and granules indicate lower dose-
dumping and inter-subject variability [5].  
Compritol 888 ATO and gelucire have been used for 
sustained release dosage form [6]. Compritol or 
glyceryl behenate has hydrophobic property with low 
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HLB value of 2 [7]. Gelucire is composed of mono- 
di and tri glycerides with polyethylene glycol esters 
of fatty acids. Gelucire is a family of vehicles with a 
range of melting point (33-66) and HLB. Gelucire 
which compose of glycerides or PEG ester same as 
gelucire 50/13 are utilized in the preparation of 
sustained release formulations [8]. 
Sodium diclofenac is a non-steroidal anti-
inflammatory drug that used to relieve the 
inflammation, stiffness, and joint pain associated with 
rheumatoid arthritis. The main side effects of the drug 
especially in case of the long-term use, may include: 
abdominal bleeding, pain or cramps, blood clotting 
problems, peptic ulcers, and vomiting. Solubility of 
Sodium diclofenac in the acidic environment such as 
the stomach (pH 1 to 3) is low and dependent to drug 
dose and gastric fluid volume [9, 10]. On the other 
hand, sodium diclofenac dissolves quickly in the 
intestinal alkaline condition so the effect of the long 
term drug uptake is impossible according to the short 
biological half life. Thus, total bioavailability of 
orally used sodium diclofenac has few important 
challenges.  
So preparing formulations of diclofenac sodium with 
a floating controlled release property not only can 
increase competence and reduce the medication side 
effects [11]. Therefore, the efforts of many 
researchers have been concerned to design a 
controlled release system for sodium diclofenac and 
other NSAID compounds [11-14]. The purpose of this 
study was to prepare and evaluate the lipid floating 
granules as a controlled drug release system for 
sodium diclofenac.  
 
Material and methods 
         Materials 
Sodium diclofenac was gift from Hakim 
pharmaceutical Company (Tehran, Iran). Compritol 
888 ATO and Gelucire 50/13 were gift from 
Gattefosse Company (France). Tween 80 and 
hydroxyl propyl methylcellulose (HPMC) were 
purchased from Merck (Germany) and sigma Aldrich 
respectively. Dialysis bag was purchased from Toba 
Azema Co, Tehran (Iran).  Minitab14 software was 
used for experimental design and the evaluation of the 
effect of variables on responses.   
  
Determination of sodium diclofenac  
           The amount of drug loading within lipid granules and 
release rate of the drug determined using UV 
spectroscopy at wavelengths of 276 nm. The validity 
of assay method including, linearity, repeatability, 
accuracy and limit of quantification (LOQ) were 
calculated.   
 
Preparation of floating granules          
In order to study the impact of independent variables 
on characteristics of granules, the full-factorial design 
with five variables and two levels were used. The 
drug-lipid proportion (d/l), amount of drug (d), drug-
HPMC proportion (d/h), percentage of Tween (%T) 
and type of lipid (l) were selected as independent and 
drug content, the percentage of drug released after 8 
hours (D8) and mean dissolution time (MDT), 
granules precipitated after 2 (P2) and 8 (P8) hours as 
floatability parameters as dependent variables (table 
1). 32 formulations were prepared based on full 
factorial design. Sustained release floating granules 
prepared with extruder- spheronization technique 
based on the method reported by Rahman et al [15]. 
Sodium diclofenac, HPMC and tween was added into 
melted lipid under stirring. The mass was stored at 
refrigerator and then forced through dies for 
providing cylindrical particles, with screw feed 
extruder equipped with 1 mm screen and operated at 
25 rpm. Spheronization was performed with rotational 
speed at 800 rpm and 1 mm serrated plate of 38 cm 
diameter.  
 
Table 1. Independent variable and their levels in 
factorial experimental design. 
 
Levels Independent 
variable 
Low (-) High(+)     
Drug (mg)     50 100 
Drug/lipid 
ratio (D/L) 1/6 1/3 
Drug/ HPMC 
ratio 1/1 1/0.4 
Tween 80 (%) 0% 1% 
Lipid type Gelucire 50/13 Compritol 
 
Drug content determination 
The drug content was calculated by extracting 
method. Defined amount of granules were accurately 
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weighed and added to 50 ml water. Mixture was 
heated to 70ºC until lipid melted. The solution was 
centrifuged, filtered and diluted. The drug content 
was measured at 276 nm [3].  
 
Morphological characterization 
Surface morphology and stability of microparticles 
were studied by SEM (VP-1455, LEO, Germany). 
Microparticles were dried and coated by gold 
palladium.  
 
Floating ability 
These experiments were performed using USP paddle 
dissolution apparatus (50 rpm, 37ºC, 200 ml) in HCL 
0.1N. Floatability time was measured by visual 
observation and the floating ability was evaluated by 
percentage of precipitated granules after 2 (P2) and 8 
(P8) hours [3].  
 
Dissolution study 
Dissolution studies for sustained release granules 
were performed in the HCL 0.1N. The release profile 
characterized using a six panel USP dissolution 
apparatus with 900 ml of medium with pH 1.2 and a 
temperature of 37◦C. Furthermore, 5 ml of dissolution 
medium were withdrawn and replaced with fresh 
dissolution medium. Absorption of samples taken 
from centrifuge and separate clear supernatant 
solution and the appropriate dilution, by 
spectrophotometer at wavelength nm 276 against the 
control (dissolution test formulations were prepared 
without the drug) [16]. For dissolution kinetic 
evaluation, the dissolution data were plotted with first 
order, zero order and hiquchi square root equation and 
the best fit was found [17]. 
 
Statistical analysis  
Minitab14 software was used for experimental design 
and the evaluation of the effect of variables on 
responses. Statistical significance of the difference 
between various treatments was performed using one-
way ANOVA. Correlation analyses were performed 
by the least square linear regression method. 
Correlation coefficients were examined for 
significance by unpaired two tailed student’s t- test.  
Significant level of choice in all stages of this 
investigation was less than 0.05.  
    
 
Results and discussion 
Validity of drug measurement method 
The relationship between the light absorption and 
concentration was significant (R2 = 0.994, P<0.001). 
Repeated surveys accountability in measurement 
methods within and between days for sodium 
diclofenac is represents the desired repeatability of 
measurement method on different days and caused 
nearly the same operation as well as error free results. 
The difference between real numbers and the 
estimated concentrations was about 5% that indicates 
the closeness of the estimated values to real results. 
The limit of quantification was 0.0005 mg/ml, but the 
only concentrations greater than 0.0006 mg / ml is 
reliable for such studies, because methods with 
concentrations higher than 0.0006 mg/ml have good 
accuracy and repeatability. Therefore in this study 
only the values greater than this cutoff were reported. 
 
Profile formulations prepared according to the 
study design 
Totally Profile of 32 floating granules formulation is 
presented in this study (Table 2). 
 
Floating lipid granules containing sodium 
diclofenac 
In order to compare the power produced by floating 
lipid granules, the number of granules to sediment 
after 2 and 8 hours and then the percentage of 
granules determined to sediment after 2 hours (P2) 
and 8 hours (P8) was calculated (Table 3). 
All the formulations prepared with Gelucire showed 
completely precipitated the good effect on the floating 
property in less than 2 hours, but Tween 80 presence 
in the formulations could not put a specific effect on 
floating property. All formulations contain no Tween 
80 were completely precipitated within less than 2 
hours. However, formulations prepared with 
Compritol 888 ATO were effective on percentage of 
the floating granules after 2 and 8 hours. Sediment 
granules percentages were between zero to 35% and 8 
to 70% after 2 and 8 hours, respectively.  
The correlation between independent variables with 
P2 and P8 is expressed by the following equations:  
%)(8/24)/(1/10)(021/0)/(1/818/88 THDDLDP ++++−=
%)(8/14)/(14/5)(046/0)/(7/4337/32 THDDLDP ++−+−=
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Table 2. Profile based on 32 formulations of granules produced by factorial design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The correlation between Tween 80 percentage, drug 
/HPMC ratio and drug/lipid ratio with P2 and P8 was 
significant in such a way that increases the 
independent variables leads to significantly increase 
in the granules sedimentation rate (Figure 1). It seems 
that in the presence of Tween 80 and HPMC with 
water absorption the floating property of the granules 
reduce. Of course the effect of Tween 80 is stronger 
than HPMC. Only interaction between the amount of 
drug and drug/HPMC ratio was thus important that 50 
mg of the drug by increasing or reducing the amount 
of the HPMC, P2 has not major change. But 100 mg 
of the drug, increase in the amount of HPMC 
significantly increased P2. In other words, drug and 
HPMC have different synergic mechanisms on the 
P2. According to the significant correlation between 
HPMC and P2, it seems that the drug boosted the 
effect HPMC on P2. 
 
Dissolution  
Dissolution data of granules prepared with Compritol 
Percentage of drug dissolved after 8 hours (D8) and 
mean dissolution time (MDT) of different granules 
are shown in table 4.  
Lipid type Tween 80 
(mg) 
HPMC  
(mg) 
Lipid 
(mg) 
Drug 
(mg) 
Factorial 
design 
condition 
Formulation  
No. 
Gelucire50/13 0% 20 150 50 - - + + -  1 
Gelucire50/13 0% 40 600 100 - - + -+  2 
Gelucire50/13 1% 50 300 50 - + - - -  3 
Compritol 1% 50 300 50  + +- - -  4 
Gelucire50/13 0% 40 300 100 - -+ + +  5 
Compritol 1% 40 300 100 + + + + + 6 
Gelucire50/13 1% 40 600 100 - + + -+  7 
Compritol 0% 20 150 50  +- + + -  8 
Gelucire50/13 0% 50 150 50 - - - + -  9 
Compritol 0% 50 300 50  +- - - -  10 
Gelucire50/13 0% 50 300 50 - - - - -  11 
Gelucire50/13 1% 20 300 50 - + + - -  12 
Compritol 1% 20 150 5 + + + +-  0 13 
Gelucire50/13 0% 100 600 100 - - - -+  14 
Gelucire50/13 1% 50 150 50 - + - + -  15 
Gelucire50/13 1% 100 600 100 - + - -+  16 
Compritol 1% 20 300 50  + + +- -  17 
Gelucire50/13 0% 50 150 50 - - + - -  18 
Compritol 0% 100 300 100  +- -+ +  19 
Compritol 11% 50 150 50  + +- + -  20 
Compritol 0% 20 300 50  +- + - -  21 
Compritol 1% 100 600 100  + +- -+  22 
Compritol 1% 20 600 100  + + +-+  23 
Gelucire50/13 1% 20 150 50 - + + + -  24 
Gelucire50/13 1% 40 300 100 -+ + + +  25 
Gelucire50/13 1% 100 300 100 - + -+ +  26 
Compritol 0% 100 600 100  +- - -+  27 
Compritol 1% 100 300 100  + +-+ +  28 
Gelucire50/13 0% 100 300 100 - - -+ +  29 
Compritol 0% 50 150 50  +- - + -  30 
Compritol 0% 40 300 100  +-+ + +  31 
Compritol 0% 40 600 100  +- + -+  32 
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The highest amount of D8 was 43.85% and achieved 
by formulation number 13. In the other hand highest 
value of MDT was 5.66 hr according to formulation 
number 14. The correlation between D/L with D8 and 
D/L and %T with MDT was significant in the manner 
that increase in D/L reduced D8 and MDT and 
increase in %T increased MDT.  
 
 
Figure 1. The correlation between independent 
variables with P2 (A) and P8 (B). 
 
The retardant effect of drug/ Compritol ratio (1:3) for 
sodium diclofenac reported previously [16]. The 
effect of D/L on D8 and MDT was due to its effect on 
drug loading. It seams that, Tween improved drug 
affinity to Compritol that is lipid carrier with HLB=2. 
The drug dissolute amount was not affected by one 
and 1/0.4 weight ratio of drug/HPMC. Similar results 
reported for carbamazepin [18]. Although, the 
importance of HPMC concentration effect on drug 
release mechanism have been reported [19; 20] but in 
present study this effect was not found. 
Analysis of dissolution kinetic was done with various 
equations such as zero order, first order and higuchi. 
r2 values calculated were shown in table 5 and drug 
dissolution profile at zero order condition 
demonstrated in figure 2.  
Results indicate that the best fit with higher 
correlation was found with higuchi equation and zero-
order for all formulations. High value of r2 for higuchi 
model indicates that diffusion is the main mechanism 
for drug release. In the other hand high value of r2 in 
zero order model demonstrates that Compritol acts as 
reservoir for diclofenac. Low affinity of sodium 
diclofenac reinforces this hypothesis. No desirable 
burst release was found for sodium diclofenac. 
 
Table 3. The percentage of granules have 
precipitated after 2 h (P2) and 8 h (P8) in the 
formulations prepared by the factorial design 
(mean ± SD, n=3). 
 
Sediment 
after 8 hours 
Sediment 
after 2 hours 
Factorial design 
condition 
Formulation 
No. 
- 100 - - + + -  1 
- 100 - - + -+  2 
- 100 - + - - -  3 
46.66± 7.63  23.23± 5.77  + +- - -  4 
- 100 - -+ + +  5 
70±8.66 35±5 + + + + + 6 
- 100 - + + -+  7 
28.33±2.88 6.66±2.88  +- + + -  8 
- 100 - - - + -  9 
21.66±7.63 8.33±2.88  +- - - -  10 
- 100 - - - - -  11 
- 100 - + + - -  12 
56.66±7.63 25±5  + + + +-  13 
- 100 - - - -+  14 
- 100 - + - + -  15 
- 100 - + - -+  16 
33.33±7.63 1 + + +- -  1.66±5.77 17 
- 100 - - + - -  18 
11.66±2.88 0  +- -+ +  19 
33.33±7.16 1 + +- + -  1.66±5.77 20 
8.33±2.88 0  +- + - -  21 
51.66±7.63 25±8.66  + +- -+  22 
58.33±7.63 30±0  + + +-+  23 
- 100 - + + + -  24 
- 100 -+ + + +  25 
18.33±7.64 5±0 - + -+ +  26 
18.33±7.64 3.33±0 + - - -+  27 
38.33±16.07 13.33±7.63  + +-+ +  28 
- 100 - - -+ +  29 
6.66±2.88 0  +- - + -  30 
48.33±7.63 15±5  +-+ + +  31 
46.64±7.63 23.33±5.77  +- + -+  32 
 
Dissolution data of granules prepared with 
gelucire 50/13 
Amount 16 formulations based on factorial design 
only 10 formulations had suitable characters and were 
used for dissolution test. Dissolution parameters 
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according to different granules prepared with gelucire 
was shown in table 6.  The highest amount of D8 was 
78.36% belongs to formulation no.8 and for MDT 
was 5.37 according to formulation no. 9. Non 
significant correlation was found between variables 
and D8 and MDT.  
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Fig 2. Dissolution profile of different granules 
prepared with Compritol. 
 
Gelucire with HLB=13 indicates hydrophilic property 
more than Compritol. The results show that sodium 
diclofenac has good affinity to gelucire and so high 
loading capacity of gelucire neutralized effect of 
independent variables. Comparision between 
dissolution parameter for two lipids indicates more 
sustained release property for Compritol. 
 
Table 4. D8 and MDT of different granules 
prepared with Compritol (mean ± SD, n=3) 
 
MDT (hr) D8 Factorial 
design 
condition 
Formulation 
No. 
0.37 ±5.44 14 +- + +  .01±1.05 1 
0.24±5.37 1.33 ±24.44 + + - + 2 
0.32 ±4.82 3 + +- -  .19±38.88 3 
0.39±4.88 2.25±33.68 - - - +  4 
0.21±5.10 25.59± 1.89 + - + +  5 
0.102 ±3.06 1.44±39.98 +  - - + 6 
0.17 ±4.63 0.98±27.02 - + + - 7 
0.24±5.21 0.33±10.28 + - + - 8 
0.16±5.26 0/78±9.68 -  + - - 9 
0.26±4.90 0.98±12.88 - - + - 10 
0.32 ±5.57 1.12±21.03 - - - - 11 
0.38±4.53 1.48±16.29 - + + + 12 
0.2±4.27 2.24 ±43.85 + - - - 13 
0.19±5.66 1.45 ±25.11 - + - + 14 
0.39±4.79 2.93 ±38.55 + + + + 15 
0.29 ±4.04 1.21±28.48 + + - - 16 
Table 5. r2 values  of granules prepared with 
Compritol in different kinetic models. 
 
Higuchi 
model 
First-
order 
Zero-
order 
Factorial 
design 
condition 
Formulation  
No. 
0.94 0.862 0.976 ++ - + 1 
0.94 0.859 0.963 + + + - 2 
0.993 0.798 0.922 - - + + 3 
0.97 0.820 0.943 - - - + 4 
0.96 0.844 0.958 + - + + 5 
0.957 0.574 0.735 + - -+ 6 
0.973 0.786 0.912 - + + _ 7 
0.967 0.790 0.96 + - + - 8 
0.974 0.790 0.959 - + - - 9 
0.981 0.805 0.927 - - + - 10 
0.963 0.90 0.983 - - - -  11 
0.991 0.80 0.914 - + + + 12 
0.998 0.74 0.890 + - - - 13 
0.938 0.90 0.982 -+ - + 14 
0.974 0.83 0.940 + + + + 15 
0.990 0.79 0.904 + + - - 16 
 
The results of dissolution kinetic analysis and drug 
dissolution profile at zero-order model are shown in 
table 7 and figure 3. r2 values indicates best fit for 
higuchi model for dissolution data and so it seams 
that diffusion across the granules is rate limiting step 
for drug release.  
 
Table 6. D8 and MDT of different granules 
prepared with gelucire (mean ± SD, n=3). 
 
MDT (hr) D8 Factorial 
design 
condition 
Formulation  
No. 
0.28 ±4.53 51.35±2.84 - + + + 1 
0.43 ±4.95 3.71 ±49.47 - + + - 2 
0.35 ±4.02 3.92±  42.23 - + - + 3 
0.39±4.50 3.11± 40.43 - + - - 4 
0.31±3.85 40.52± 2.08 - - + + 5 
0.22 ±4.65 1.95± 43.47 - - + - 6 
0.19 ±4.03 4.41± 76.83 + - - + 7 
0.28±4.41 6.33±  78.36 + - - - 8 
0.14±5.36 2.96±  65.68 - - - + 9 
0.18±5.250 5.83±  66.14 - - - - 10 
 
In comparison with Compritol, gelucire did not act as 
reservoir system because the lower value of r2. higher 
hydrophilic property of gelucire tends to water 
absorption and improves drug release. 
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Figure 3. Dissolution profile of different granules 
prepared with gelucire. 
 
Particles morphology 
The SEM photomicrographs of granules prepared 
with Compritol are shown in figure 4. In these 
pictures effect of tween and dissolution condition on 
appearance and particle size were evaluated. Results 
suggested creation pores with tween at the surface of 
particles (B) after dissolution test.  
 
Table 7. r2 values  of granules prepared with 
gelucire in different kinetic models. 
 
Higuchi 
model 
First-
order 
Zero-
order 
Factorial 
design 
condition 
Formulation 
No. 
0.984 0.764 0.914 + + - + 1 
0.965 0.826 0.934 + + + - 2 
0.986 0.688 0.896 - - + + 3 
0.979 0.780 0.908 - - - + 4 
0.993 0.650 0.843 + - + + 5 
0.980 0.8 0.924 + - - + 6 
0.985 0.731 0.856 - + + - 7 
0.980 0.770 0.908 + - + - 8 
0.970 0.870 0.965 - + - -  9 
0.940 0.880 0.951 - - + - 10 
 
These pores were not seen in particles without tween 
(D). In the other hand, the particle size was not 
affected by dissolution test and in both condition 
particle size was in range of 5-10 µm. these results 
conforming calculated dissolution parameters. 
 
Conclusion 
The sodium diclofenac loaded floating granules were 
prepared by extruder-spheronization method with two 
type of lipid successfully. Floating ability of sustained 
release granules to be touched by Tween 80 
percentage, drug /HPMC ratio and drug/lipid ratio.  
 
   
(a) (b) 
    
(c) (d) 
 
Figure 4. SEM photomicrographs of particle with 
tween before (a) and after (b) dissolution test and 
particles without tween before (c) and after (d) 
dissolution test. 
 
All the formulations prepared with Gelucire showed 
completely precipitated less than 2 hrs and 
formulations prepared with Compritol 888 ATO were 
effective on percentage of the floating granules after 2 
and 8 hours. Compritol granules provided suitable 
sustained release pattern in the manner that increase 
in D/L reduced D8 and MDT and increase in %T 
increased MDT. Higuchi model was the best fitted for 
dissolution data of granules prepared by Compritol 
and gelucire. In conclusion, Compritol provided more 
suitable floating ability and sustained release 
property.  
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